TABLE 1.

Caspofungin MICs and PG characteristics for 30 clinical Candida sp. isolates in planktonic and biofilm growth forms

Isolate no.	Species	Planktonic cells		Biofilms
		MIC (μg/ml)a	Drug concn range (μg/ml) producing PGb	MIC (μg/ml)c	Drug concn range (μg/ml) producing PG
BR-A1	C. albicans	0.5	NAd	4	8-128
BR-A2	C. albicans	0.5	16	2	8-128
BR-A4	C. albicans	0.5	NA	2	16-128
BR-A7	C. albicans	0.5	NA	2	16-128
BR-A8	C. tropicalis	1	8	2	4-32
BR-A9	C. tropicalis	1	8	2	4-32
BR-A14	C. tropicalis	0.5	8	256	NA
BR-A18	C. tropicalis	0.5	NA	128	NA
BR-A20	C. tropicalis	0.5	NA	2	8-64
BR-A24	C. tropicalis	1	NA	2	8-64
BR-A25	C. parapsilosis	2	32	2	16-256
BR-A26	C. parapsilosis	2	16-32	256	NA
BR-A27	C. parapsilosis	2	NA	256	NA
BR-A28	C. parapsilosis	2	NA	2	16-128
BR-A29	C. parapsilosis	2	32-64	4	16-128
BR-A30	C. parapsilosis	2	NA	256	NA
BR-A31	C. parapsilosis	2	NA	4	32-64
BR-A32	C. orthopsilosis	2	NA	2	32-64
BR-A33	C. orthopsilosis	1	NA	2	32-64
BR-A34	C. orthopsilosis	1	4	2	32-128
BR-A35	C. orthopsilosis	1	NA	2	16-128
BR-A36	C. orthopsilosis	1	NA	2	16-128
BR-A37	C. orthopsilosis	2	32-64	2	32-64
BR-A38	C. orthopsilosis	2	16-64	512	NA
BR-A39	C. orthopsilosis	2	NA	2	32-128
BR-A40	C. metapsilosis	1	NA	2	16-64, 512
BR-A41	C. metapsilosis	2	NA	2	16
BR-A42	C. metapsilosis	1	NA	2	32-64
BR-A43	C. metapsilosis	2	NA	2	16
BR-A44	C. metapsilosis	2	NA	2	16
22019	C. parapsilosis	2	8	2	16-128

^aMIC endpoint based on visual determination of the lowest drug concentration that produced a prominent decrease in growth relative to that for the drug-free growth control well.

^bDrug concentration(s) above the MIC with visible growth ≥20% for planktonic cells and ≥50% for biofilm cells relative to the growth for the drug-free growth control.

^cMIC endpoint based on the lowest drug concentration producing a 50% reduction in metabolic activity relative to that for the drug-free growth control, as measured by the XTT reduction assay.

^dNA, no PG observed.